UK regulators have tightened safety rules and prescribing oversight for GLP-1 weight-loss and diabetes treatments, including Wegovy, Mounjaro and the newly launched oral pill Foundayo, following updated safety warnings and stricter pharmacy checks.
New daily tablets approved in the UK
Dr Kate Bunyan, medical director at heart health check provider PocDoc, described the sector as a "fast-moving area" with new products recently entering the UK. She explained: "This year, two daily weight loss tablets have been approved in the UK: the Wegovy pill (oral semaglutide) in June and Foundayo (orforglipron) in August. The UK was the first country in Europe to authorise orforglipron."
Dr Bunyan urged people to "follow the instructions for your specific medicine", as tablet medications have different rules than injections. She pointed out that for now, neither the Wegovy pill nor the Foundayo pill are available on the NHS.
Safety warnings and pharmacy checks
In November 2026, the US FDA ordered updated safety labels across GLP-1 medications to warn of a rare eye condition linked to sudden vision loss (NAION), aligning with earlier UK MHRA updates on vision risks and acute pancreatitis.
UK regulators have also reinforced strict rules against using these medications during pregnancy or breastfeeding and tightened oversight on online pharmacies to ensure thorough consultations before dispensing. Despite tighter regulation, these prescription-only treatments remain available in the UK, including newer daily oral options such as Foundayo and oral Wegovy, and patients are advised to report any vision changes promptly rather than stopping treatment without medical advice.
Access and future changes
Dr Bunyan said: "For most people, access to these medicines is still through private prescription. That may change soon, as NICE (National Institute for Health and Care Excellence)—which decides which medicines the NHS funds—is expected to publish its decision on orforglipron imminently."
She added: "Regulation has tightened. Online pharmacies must now independently verify a person’s weight or BMI before prescribing, rather than relying on a questionnaire." There are also concerns about bogus weight loss medicines being sold to people trying to lose weight.
Avoiding fake products
The expert said: "The MHRA (Medicines and Healthcare products Regulatory Agency) has also warned about fake pens and businesses advertising medicines that aren't yet authorised. If a product is sold without a proper consultation, or offered before it's been approved, avoid it."
Dr Bunyan said that while many of these medications are not new, the key shift now is in "broadening what we use these medicines for". She said: "Wegovy is now licensed to reduce the risk of heart attack and stroke in people with existing cardiovascular disease, showing that these treatments are about long-term health as well as weight."
Expanding support and metabolic health
Given these trends, providers may expand further the support they offer to people looking to lose weight with these treatments. Dr Bunyan said: "I expect we'll see more focus on metabolic health—how well your body manages things like blood sugar, cholesterol, and blood pressure. These affect the health of your heart and kidneys, as well as your risk of stroke and type 2 diabetes, and they can start to improve well before you reach your target weight. We'll also see more emphasis on matching each patient to the right treatment."